Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

杜鲁特格拉维尔 埃法维伦兹 医学 养生 拉米夫定 病毒载量 临床终点 内科学 恩曲他滨 随机对照试验 人类免疫缺陷病毒(HIV) 病毒学 抗逆转录病毒疗法 病毒 乙型肝炎病毒
作者
Alexandra Calmy,Tamara Tovar Sanchez,Charles Kouanfack,Mireille Mpoudi-Etame,Sandrine Leroy,Ségolène Perrineau,Martial Lantche Wandji,Darius Tetsa Tata,Pierette Omgba Bassega,Thérèse Abong Bwenda,Marie Varloteaux,Marcel Tongo,Eitel Mpoudi‐Ngolé,Alice Montoyo,Noémie Mercier,Vincent Le Moing,Martine Peeters,Jacques Reynes,Éric Delaporte,Alexandra Calmy
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:7 (10): e677-e687 被引量:168
标识
DOI:10.1016/s2352-3018(20)30238-1
摘要

Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy of dolutegravir compared with efavirenz 400 mg at week 96.We did a multicentre, randomised, open label, phase 3 trial in in three hospitals in Yaoundé, Cameroon, in HIV-1 infected antiretroviral-naive adults with an HIV RNA viral load of greater than 1000 copies per mL to compare dolutegravir 50 mg with efavirenz 400 mg (reference treatment), both combined with lamivudine and tenofovir disoproxil fumarate. The primary endpoint was the proportion with a viral load of less than 50 copies per mL at week 48 (10% non-inferiority margin). The study is registered with ClinicalTrials.gov, NCT02777229 and is ongoing.Between July, 2016, and August, 2019, of 820 patients assessed, 613 were randomly assigned to receive at least one dose of study medication, with 310 in the dolutegravir group and 303 in the efavirenz 400 mg group. At week 96 in the intention-to-treat analysis, 229 (74%) of 310 patients receiving dolutegravir and 219 (72%) of 303 patients receiving efavirenz, achieved plasma HIV-1 RNA less than 50 copies per mL (difference 1·6%, 95% CI -5·4 to 8·6; p=0.66). Viral load suppression was reached significantly more rapidly in the dolutegravir group (p<0·001). Virological failure (>1000 copies per mL) was observed in 27 patients (eight in the dolutegravir group, among which, three women switched to efavirenz 600 mg because of the dolutegravir teratogeneicity signal, and 19 in the efavirenz 400 mg group). No acquired resistance mutations to dolutegravir were observed against 17 mutations to efavirenz with or without mutations to lamivudine and tenofovir disoproxil fumarate among the 19 efavirenz 400 mg participants with virological failure. Weight gain was greater in the dolutegravir group (median weight gain, 5·0 kg in the dolutegravir group and 3·0 kg in the efavirenz 400 mg group, p<0·001, and incidence of obesity, 22% in the dolutegravir group and 16% in the efavirenz 400 mg group, p=0·043). The incidence of new WHO HIV-related stage 3 and 4 events was similar in each group (12 [4%] in each group). The two groups had similar rates of serious adverse events (28 [9%] of 310 in the dolutegravir group and 21 [7%] of 303 in the efavirenz 400 mg group). 18 deaths were observed during the 96-week follow-up (eight in the dolutegravir group and ten in the efavirenz 400 mg group).The non-inferior efficacy of the dolutegravir-based regimen and non-emergence of dolutegravir resistance at 96 weeks supports its use as a first-line regimen for antiretroviral-naive adults with HIV-1 infection. Viral load suppression was reached more quickly in the dolutegravir group and weight gain was significantly higher.UNITAID and the French National Agency for AIDS Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
yummy发布了新的文献求助10
2秒前
苏凉发布了新的文献求助10
3秒前
焱焱不忘完成签到 ,获得积分0
3秒前
Jun的应助被无辜冷雁采纳,获得10
3秒前
3秒前
念青唐发布了新的文献求助10
3秒前
vv发布了新的文献求助10
4秒前
Brandy完成签到,获得积分10
4秒前
魁梧的熊猫完成签到,获得积分10
4秒前
米米发布了新的文献求助10
5秒前
cc晒泰阳发布了新的文献求助10
5秒前
归一完成签到 ,获得积分10
5秒前
猪猪hero发布了新的文献求助10
5秒前
Dongcong完成签到,获得积分0
5秒前
saveMA完成签到,获得积分10
6秒前
稳重的道天完成签到,获得积分10
7秒前
7秒前
8秒前
李健的小迷弟的应助被玩家666采纳,获得10
8秒前
xigu发布了新的文献求助10
8秒前
坚强从筠完成签到,获得积分20
8秒前
胜似闲庭信步完成签到,获得积分10
9秒前
9秒前
ZZZZ完成签到,获得积分10
9秒前
小二郎的应助被luhanwei采纳,获得10
9秒前
归一关注了科研通微信公众号
9秒前
纤维砖家发布了新的文献求助10
9秒前
孝顺的猫完成签到,获得积分10
9秒前
语兰完成签到 ,获得积分10
10秒前
10秒前
傻傻的初柳完成签到,获得积分10
10秒前
香蕉觅云的应助被孤独代亦采纳,获得10
11秒前
11秒前
luo发布了新的文献求助10
11秒前
鲤鱼灵波发布了新的文献求助10
11秒前
11秒前
极限001的应助被CangZm1采纳,获得30
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695